Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Neuroectodermal Tumors

ClinicalTrials.gov lists 8,507 trials for Neuroectodermal Tumors or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 554.

MeSH D017599 Neoplasms Neoplasm C04
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 2,126 Phase 1/2 Phase 1/2 958 Phase 2 Phase 2 2,376 Phase 2/3 Phase 2/3 62 Phase 3 Phase 3 436 Phase 4 Phase 4 74 Not applicable Not applicable 1,012 Observational Observational 1,390 Phase 1 Phase 1 2,126 Phase 1/2 Phase 1/2 958 Phase 2 Phase 2 2,376 Phase 2/3 Phase 2/3 62 Phase 3 Phase 3 436 Phase 4 Phase 4 74 Not applicable Not applicable 1,012 Observational Observational 1,390

Trials per phase (log scale)

1 more section with rows

28 of the 8,507 trials are tagged with Neuroectodermal Tumors itself; the rest are tagged with a narrower condition beneath it.

Get the Neuroectodermal Tumors report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Neuroectodermal Tumors trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 31 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 447

1990: 6 trials (Observational 2, Not applicable 1, Phase 3 2, Phase 2 1) 1991: 8 trials (Observational 3, Not applicable 1, Phase 2 2, Phase 1 2) 1992: 9 trials (Observational 2, Not applicable 3, Phase 3 2, Phase 2 2) 1993: 8 trials (Observational 1, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 1994: 15 trials (Observational 1, Phase 3 3, Phase 2 7, Phase 1 4) 1995: 30 trials (Observational 5, Phase 3 5, Phase 2 12, Phase 1/2 2, Phase 1 6) 1996: 46 trials (Observational 4, Not applicable 1, Phase 3 5, Phase 2 23, Phase 1/2 1, Phase 1 12) 1997: 52 trials (Observational 6, Not applicable 1, Phase 3 3, Phase 2 21, Phase 1/2 7, Phase 1 14) 1998: 77 trials (Observational 6, Not applicable 3, Phase 3 5, Phase 2/3 2, Phase 2 39, Phase 1/2 6, Phase 1 16) 1999: 101 trials (Observational 9, Phase 3 11, Phase 2 51, Phase 1/2 6, Phase 1 24) 2000: 103 trials (Observational 11, Not applicable 5, Phase 3 10, Phase 2 29, Phase 1/2 20, Phase 1 28) 2001: 115 trials (Observational 7, Not applicable 4, Phase 4 1, Phase 3 12, Phase 2 40, Phase 1/2 16, Phase 1 35) 2002: 117 trials (Observational 7, Not applicable 6, Phase 3 12, Phase 2 41, Phase 1/2 20, Phase 1 31) 2003: 123 trials (Observational 15, Not applicable 9, Phase 4 2, Phase 3 7, Phase 2/3 1, Phase 2 57, Phase 1/2 12, Phase 1 20) 2004: 168 trials (Observational 19, Not applicable 14, Phase 3 15, Phase 2/3 1, Phase 2 63, Phase 1/2 17, Phase 1 39) 2005: 217 trials (Observational 18, Not applicable 14, Phase 3 15, Phase 2/3 2, Phase 2 85, Phase 1/2 23, Phase 1 60) 2006: 219 trials (Observational 28, Not applicable 10, Phase 4 2, Phase 3 16, Phase 2/3 1, Phase 2 85, Phase 1/2 26, Phase 1 51) 2007: 226 trials (Observational 28, Not applicable 12, Phase 4 2, Phase 3 16, Phase 2/3 2, Phase 2 91, Phase 1/2 22, Phase 1 53) 2008: 251 trials (Observational 55, Not applicable 15, Phase 4 2, Phase 3 15, Phase 2 91, Phase 1/2 17, Phase 1 56) 2009: 264 trials (Other 1, Observational 34, Not applicable 20, Phase 4 1, Phase 3 15, Phase 2/3 2, Phase 2 88, Phase 1/2 32, Phase 1 71) 2010: 283 trials (Observational 33, Not applicable 14, Phase 4 1, Phase 3 14, Phase 2 105, Phase 1/2 38, Phase 1 78) 2011: 283 trials (Observational 41, Not applicable 27, Phase 4 3, Phase 3 13, Phase 2/3 5, Phase 2 90, Phase 1/2 25, Phase 1 79) 2012: 263 trials (Observational 40, Not applicable 34, Phase 4 4, Phase 3 13, Phase 2/3 1, Phase 2 72, Phase 1/2 32, Phase 1 67) 2013: 316 trials (Observational 49, Not applicable 38, Phase 4 6, Phase 3 16, Phase 2 93, Phase 1/2 24, Phase 1 90) 2014: 327 trials (Observational 49, Not applicable 40, Phase 4 3, Phase 3 12, Phase 2/3 3, Phase 2 96, Phase 1/2 37, Phase 1 87) 2015: 363 trials (Other 1, Observational 52, Not applicable 48, Phase 4 8, Phase 3 17, Phase 2/3 3, Phase 2 96, Phase 1/2 47, Phase 1 91) 2016: 361 trials (Observational 70, Not applicable 37, Phase 4 3, Phase 3 12, Phase 2/3 2, Phase 2 81, Phase 1/2 43, Phase 1 113) 2017: 391 trials (Observational 67, Not applicable 54, Phase 4 3, Phase 3 15, Phase 2/3 3, Phase 2 114, Phase 1/2 46, Phase 1 89) 2018: 400 trials (Observational 76, Not applicable 58, Phase 4 3, Phase 3 17, Phase 2/3 8, Phase 2 74, Phase 1/2 54, Phase 1 110) 2019: 378 trials (Observational 75, Not applicable 57, Phase 4 4, Phase 3 9, Phase 2/3 3, Phase 2 95, Phase 1/2 43, Phase 1 92) 2020: 392 trials (Observational 69, Not applicable 58, Phase 4 2, Phase 3 11, Phase 2/3 3, Phase 2 95, Phase 1/2 50, Phase 1 104) 2021: 438 trials (Observational 82, Not applicable 71, Phase 4 2, Phase 3 13, Phase 2/3 3, Phase 2 109, Phase 1/2 52, Phase 1 106) 2022: 447 trials (Observational 97, Not applicable 72, Phase 4 4, Phase 3 21, Phase 2/3 1, Phase 2 90, Phase 1/2 47, Phase 1 115) 2023: 390 trials (Observational 88, Not applicable 64, Phase 4 4, Phase 3 20, Phase 2/3 4, Phase 2 71, Phase 1/2 49, Phase 1 90) 2024: 388 trials (Observational 102, Not applicable 67, Phase 4 2, Phase 3 14, Phase 2/3 4, Phase 2 78, Phase 1/2 39, Phase 1 82) 2025: 402 trials (Observational 81, Not applicable 70, Phase 4 5, Phase 3 19, Phase 2/3 5, Phase 2 71, Phase 1/2 46, Phase 1 105)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 375
2025 402
2024 388
2023 390
2022 447
2021 438
2020 392
2019 378
2018 400
2017 391

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 400 trials starting in 2026 and about 400 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 1,024 trials still running at the 2026-10-09 snapshot; registered median of 40 months across 5,073 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Neuroectodermal Tumors trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 2,126
Phase 1/2 958
Phase 2 2,376
Phase 2/3 62
Phase 3 436
Phase 4 74
Not applicable 1,012
Observational 1,390
Expanded access 73

How many Neuroectodermal Tumors trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 301
Recruiting 1,234
Enrolling by invitation 44
Active, not recruiting 659
Available 18

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Neuroectodermal Tumors trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 554
Children's Oncology Group 106
Novartis Pharmaceuticals 104
Bristol-Myers Squibb 92
Hoffmann-La Roche 61

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Neuroectodermal Tumors? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEMBROLIZUMAB 328
NIVOLUMAB 299
Cytoxan 288
IPILIMUMAB 255
Irinotecan 97

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SOC: Temozolomide 566
Radiation Therapy 258
Bevacizumab 1 219
or carboplatin 163
Etoposid 137

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Neuroectodermal Tumors trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Malignant neoplasm progression 2,241 77
Pyrexia 1,961 272
Pneumonia 1,726 291
Fatigue 1,600 359
Vomiting 1,552 475

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Neuroectodermal Tumors? (11)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. European urology 2022 Yes
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell 2016 Yes
Evaluation of the diagnostic performance of magnetic resonance spectroscopy in brain tumors: a systematic review and meta-analysis. PloS one 2014 Yes
Trilateral retinoblastoma: neuroimaging characteristics and value of routine brain screening on admission. Journal of neuro-oncology 2012 Yes
EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. European journal of nuclear medicine and molecular imaging 2008 Yes

Showing 5 of 11 publications.

Start your 14-day trial Email me all 11 publications as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages